JP2022101535A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022101535A5 JP2022101535A5 JP2022036164A JP2022036164A JP2022101535A5 JP 2022101535 A5 JP2022101535 A5 JP 2022101535A5 JP 2022036164 A JP2022036164 A JP 2022036164A JP 2022036164 A JP2022036164 A JP 2022036164A JP 2022101535 A5 JP2022101535 A5 JP 2022101535A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- subject
- use according
- weeks
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19189442 | 2019-07-31 | ||
| EP19189442 | 2019-07-31 | ||
| EP20174790 | 2020-05-14 | ||
| EP20174790 | 2020-05-14 | ||
| EP20179591 | 2020-06-11 | ||
| EP20179591 | 2020-06-11 | ||
| JP2020129462A JP7437261B2 (ja) | 2019-07-31 | 2020-07-30 | 抗ｃ５抗体クロバリマブの使用によるｃ５関連疾患の治療または予防のための薬用量および投与レジメン |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020129462A Division JP7437261B2 (ja) | 2019-07-31 | 2020-07-30 | 抗ｃ５抗体クロバリマブの使用によるｃ５関連疾患の治療または予防のための薬用量および投与レジメン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022101535A JP2022101535A (ja) | 2022-07-06 |
| JP2022101535A5 true JP2022101535A5 (enExample) | 2023-08-09 |
| JP7748311B2 JP7748311B2 (ja) | 2025-10-02 |
Family
ID=71846415
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020129462A Active JP7437261B2 (ja) | 2019-07-31 | 2020-07-30 | 抗ｃ５抗体クロバリマブの使用によるｃ５関連疾患の治療または予防のための薬用量および投与レジメン |
| JP2022036164A Active JP7748311B2 (ja) | 2019-07-31 | 2022-03-09 | 抗ｃ５抗体クロバリマブの使用によるｃ５関連疾患の治療または予防のための薬用量および投与レジメン |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020129462A Active JP7437261B2 (ja) | 2019-07-31 | 2020-07-30 | 抗ｃ５抗体クロバリマブの使用によるｃ５関連疾患の治療または予防のための薬用量および投与レジメン |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220275070A1 (enExample) |
| EP (1) | EP4003409A1 (enExample) |
| JP (2) | JP7437261B2 (enExample) |
| KR (2) | KR20240033090A (enExample) |
| CN (2) | CN114929273A (enExample) |
| AU (1) | AU2020322165A1 (enExample) |
| CA (1) | CA3144923A1 (enExample) |
| CR (1) | CR20220041A (enExample) |
| IL (1) | IL288600A (enExample) |
| MX (1) | MX2022001154A (enExample) |
| TW (1) | TWI886140B (enExample) |
| WO (1) | WO2021019036A1 (enExample) |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| DE69937291T2 (de) | 1998-04-02 | 2008-07-10 | Genentech, Inc., South San Francisco | Antikörpervarianten und fragmente davon |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| BR0008758A (pt) | 1999-01-15 | 2001-12-04 | Genentech Inc | Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante |
| AU2001296594A1 (en) | 2000-10-10 | 2002-04-22 | Tanox, Inc. | Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection |
| US7432356B2 (en) | 2001-08-17 | 2008-10-07 | Genentech, Inc. | Complement pathway inhibitors binding to C5 and C5a without preventing formation of C5b |
| ITMI20021527A1 (it) | 2002-07-11 | 2004-01-12 | Consiglio Nazionale Ricerche | Anticorpi anti componente c5 del complemento e loro uso |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| PT1572744E (pt) | 2002-12-16 | 2010-09-07 | Genentech Inc | Variantes de imunoglobulina e utilizações destas |
| US20050169921A1 (en) | 2004-02-03 | 2005-08-04 | Leonard Bell | Method of treating hemolytic disease |
| US20070116710A1 (en) | 2004-02-03 | 2007-05-24 | Leonard Bell | Methods of treating hemolytic anemia |
| BR122019012028B1 (pt) | 2004-04-13 | 2023-09-26 | F. Hoffmann-La Roche Ag | Anticorpos anti-p-selectina, molécula de ácido nucléico, vetor, e composição |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| DK2359834T5 (en) | 2006-03-15 | 2017-02-06 | Alexion Pharma Inc | Treatment of paroxysmal nocturnal hemoglobinuria patients with a complement inhibitor |
| WO2010015608A1 (en) | 2008-08-05 | 2010-02-11 | Novartis Ag | Compositions and methods for antibodies targeting complement protein c5 |
| RS64039B1 (sr) | 2008-11-10 | 2023-04-28 | Alexion Pharma Inc | Metode i kompozicije za lečenje poremećaja povezanih sa komplementom |
| HUE056489T2 (hu) | 2014-12-19 | 2022-02-28 | Chugai Pharmaceutical Co Ltd | Anti-C5 antitestek és alkalmazási eljárások |
| DK3390442T5 (da) | 2015-12-18 | 2024-09-23 | Chugai Pharmaceutical Co Ltd | Anti-C5 antistoffer og fremgangsmåde til anvendelse deraf |
| US20190023775A1 (en) | 2016-01-11 | 2019-01-24 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment |
| WO2017132259A1 (en) | 2016-01-25 | 2017-08-03 | Shire Human Genetic Therapies, Inc. | Anti-c5 antibodies with enhanced ph switch |
| EP3554543A4 (en) * | 2016-12-16 | 2020-09-02 | Samsung Bioepis Co., Ltd. | STABLE Aqueous ANTI-C5 ANTIBODY COMPOSITION |
| CN110167961A (zh) * | 2017-01-31 | 2019-08-23 | 中外制药株式会社 | 用于治疗或预防c5相关疾病的药物组合物和治疗或预防c5相关疾病的方法 |
| KR20200070355A (ko) * | 2017-10-26 | 2020-06-17 | 알렉시온 파마슈티칼스, 인코포레이티드 | 발작성 야간 혈색소뇨 (pnh) 및 비정형 용혈성 요독 증후군 (ahus)의 치료를 위한 항-c5 항체의 투여량 및 투여 |
-
2020
- 2020-07-30 CN CN202080054557.7A patent/CN114929273A/zh active Pending
- 2020-07-30 EP EP20747415.6A patent/EP4003409A1/en active Pending
- 2020-07-30 CA CA3144923A patent/CA3144923A1/en active Pending
- 2020-07-30 MX MX2022001154A patent/MX2022001154A/es unknown
- 2020-07-30 US US17/630,046 patent/US20220275070A1/en active Pending
- 2020-07-30 CN CN202210578978.0A patent/CN115068604A/zh active Pending
- 2020-07-30 CR CR20220041A patent/CR20220041A/es unknown
- 2020-07-30 KR KR1020247006223A patent/KR20240033090A/ko active Pending
- 2020-07-30 KR KR1020207030736A patent/KR20210016333A/ko not_active Ceased
- 2020-07-30 AU AU2020322165A patent/AU2020322165A1/en active Pending
- 2020-07-30 WO PCT/EP2020/071555 patent/WO2021019036A1/en not_active Ceased
- 2020-07-30 TW TW109125890A patent/TWI886140B/zh active
- 2020-07-30 JP JP2020129462A patent/JP7437261B2/ja active Active
-
2021
- 2021-12-01 IL IL288600A patent/IL288600A/en unknown
-
2022
- 2022-03-09 JP JP2022036164A patent/JP7748311B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018141025A5 (enExample) | ||
| JP4177455B2 (ja) | 逆キメラおよびハイブリッドオリゴヌクレオチド | |
| KR101197799B1 (ko) | 용혈성 질환을 치료하는 방법 | |
| RS53864B1 (sr) | Produžavanje preživljavanja alografta inhibiranjem aktivnosti komplementa | |
| BRPI0718830A2 (pt) | Métodos para tratar anemia hemolítica | |
| EP3344772A1 (en) | Antagonistic pdl1 aptamers and their applications in cancer therapy | |
| JP2009521234A (ja) | 補体系を制御する組成および方法 | |
| JP2002528513A (ja) | Ｐ−セレクチンリガンド（ｐｓｇｌ）アンタゴニストによる細胞毒性ｔ−細胞分化の阻害 | |
| JP2007119493A (ja) | γグロブリンの投与によるガン性疾患を処置するための免疫療法 | |
| JP2022535127A (ja) | アルファ－１アンチトリプシン欠乏症（ａａｔｄ）の治療法 | |
| JP2022104920A5 (enExample) | ||
| WO2017139616A1 (en) | Methods of treatment for alpha-1 antitrypsin deficiency | |
| JP2022101535A5 (enExample) | ||
| JP6702938B2 (ja) | アンタゴニストｉｃ ｃｔｌａ−４アプタマー及びその免疫活性増強への応用 | |
| WO2018214860A1 (zh) | 治疗再生障碍性贫血的方法和药物组合物 | |
| Chan et al. | High-dose sequential chemotherapy and autologous stem cell reinfusion in advanced pediatric solid tumors | |
| JPH11512601A (ja) | 修飾プロテインキナーゼａ特異的オリゴヌクレオチドおよびその使用法 | |
| RU2022103731A (ru) | Дозировка и схема введения для лечения или предупреждения связанных с с5 заболеваний посредством применения антитела против с5 кровалимаба | |
| RU2022103727A (ru) | Дозировка и схема введения для лечения или предупреждения связанных с с5 заболеваний посредством применения антитела против с5 кровалимаба | |
| RU2024137801A (ru) | Дозировка и схема введения для лечения или предупреждения связанных с С5 заболеваний посредством применения антитела против С5 кровалимаба | |
| CN120112639A (zh) | Angptl3相关疾病和病症的治疗方法 | |
| JP3168005B2 (ja) | 病気の処置 | |
| CN112472803A (zh) | 抗pd-1抗体和抗ctla-4抗体的组合在制备治疗肾癌药物中的应用 | |
| RU2023101857A (ru) | Фармацевтическая композиция, предназначенная для применения для лечения или предупреждения связанного с c5 заболевания, и способ лечения или предупреждения связанного с c5 заболевания | |
| WO1997024130A1 (en) | CANCEROUS METASTASIS INHIBITOR COMPRISING SURFACE POLYSACCHARIDE OF STREPTOCOCCUS AGALACTIAE Ia TYPE OR Ib TYPE AS PRINCIPAL COMPONENT |